File(s) under permanent embargo
Clinical association between pharmacogenomics and adverse drug reactions
journal contribution
posted on 2015-04-01, 00:00 authored by Z W Zhou, X W Chen, K B Sneed, Y X Yang, X Zhang, Z X He, K Chow, T Yang, Wei DuanWei Duan, S F ZhouAdverse drug reactions (ADRs) are a major public health concern and cause significant patient morbidity and mortality. Pharmacogenomics is the study of how genetic polymorphisms affect an individual's response to pharmacotherapy at the level of a whole genome. This article updates our knowledge on how genetic polymorphisms of important genes alter the risk of ADR occurrence after an extensive literature search. To date, at least 244 pharmacogenes identified have been associated with ADRs of 176 clinically used drugs based on PharmGKB. At least 28 genes associated with the risk of ADRs have been listed by the Food and Drug Administration as pharmacogenomic biomarkers. With the availability of affordable and reliable testing tools, pharmacogenomics looks promising to predict, reduce, and minimize ADRs in selected populations.
History
Journal
DrugsVolume
75Issue
6Pagination
589 - 631Publisher
SpringerLocation
Basel, SwitzerlandPublisher DOI
ISSN
0012-6667eISSN
1179-1950Language
engPublication classification
C Journal article; C1 Refereed article in a scholarly journalCopyright notice
2015, SpringerUsage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC